Vimarsana
Biggest News Aggregation in the World

Page 17 - Expanded Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Access Today - Breaking & Trending Today

Data Bridge Market Research: E-Clinical Solutions Market Size to Surpass USD 20.54 Billion by 2029, Size, Share, Emerging Trends, Business Strategies and Competitive Landscape - Vimarsana News

Data Bridge Market Research: E-Clinical Solutions Market Size to Surpass USD 20.54 Billion by 2029, Size, Share, Emerging Trends, Business Strategies and Competitive Landscape

BOSTON, Jan. 12, 2023 /PRNewswire/ -- Data Bridge Market Research has recently published a Report, titled, "E-Clinical Solutions Market" The report offers an extensive analysis of key growth

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab - Vimarsana News

Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

The second Expanded Access patient (EA2) demonstrated additional clinical improvement in the Expanded Disability Status Scale (EDSS), a FDA recognized standard clinical outcome assessment score NEW

Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab - Vimarsana News

Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the second patient (“EA2”) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal ...

Psychedelic Drugs – Easing The Regulatory Hurdles For Development - Healthcare - Vimarsana News

Psychedelic Drugs – Easing The Regulatory Hurdles For Development - Healthcare

Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are potentially useful in treating...

Source: mondaq.com
Congress Introduces Expansion of Therapeutic Psychedelic Therapies - Vimarsana News

Congress Introduces Expansion of Therapeutic Psychedelic Therapies

Congress recently introduced a bill that could expand access to therapeutic psychedelics that are designated as Breakthrough Therapies. These products are useful in treating addiction, depression, post-traumatic stress disorder PTSD, and other neurologic diseases.